T he Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment (ExTRACT)-Thrombolysis in Myocardial Infarction (TIMI)-25 study 1 demonstrated that the administration of enoxaparin sodium, 30 mg intravenously, followed by subcutaneous injections of 1 mg/kg twice daily (dose modified in patients 75 years or older), compared with intravenous unfractionated heparin (UFH), 60 U/kg bolus (maximum 4000 U), followed by 12 U/kg/h (initial maximum, 1000 U/h, and subsequently adjusted to maintain an activated partial thromboplastin time of 1.5-2.0 times the control value), reduced the risk of nonfatal reinfarction in patients with ST elevation myocardial infarction (STEMI) treated with thrombolysis. Because the ExTRACT-TIMI 25 study seems likely to be the last large trial evaluating the efficacy and safety of lowmolecular-weight heparin (LMWH) in patients with STEMI, we added the results of this pivotal 20 000 patient trial to our meta-analysis published in 2005. 2 Our updated literature search identified 1 additional study by Wang and colleagues 3 published in 2006 involving 186 patients with STEMI who were randomized to receive parnaparin sodium or UFH; this study was also added to our meta-analysis.
Including the ExTRACT-TIMI 25 study and the study by Wang and colleagues, 3 (Table) . The rates of death were not significantly different in the 2 treatment groups (5.3% vs 5.8%) (OR, 0.92; 95% CI, 0.83-1.02), but LMWH compared with UFH significantly increased major bleeding events (2.2% vs 1.6%) (OR, 1.39; 95% CI, 1.17-1.66) (number needed to harm [NNH], 167) and minor bleeding events (7.2% vs 5.8%) (OR, 1.31; 95% CI, 1.18-1.45) (NNH, 71). The benefit of LMWH in reducing reinfarction remained evident at 30 days, and estimates for other outcomes were similar at 7 and 30 days. Stroke rates were identical in the 2 randomized treatment groups at 30 days.
The inclusion of data from the ExTRACT-TIMI 25 study 1 and the study by Wang et al 3 in our meta-analysis substantially increased the number of outcome events (number of reinfarctions increased from 253 events to 1043 events; death, from 412 events to 1911 events; and major bleeding events, from 206 events to 520 events), thereby greatly improving the precision of the estimates of effect size. A reduced risk of reinfarction became evident after the first trial in 2001, when 4078 patients had been randomized and 144 reinfarctions had occurred ( Figure) . Cumulative data from subsequent trials resulted in a narrowing of the 95% CI, but the point estimates remained similar. A statistically significant increase in the risk of major bleeding with LMWH compared with UFH was not evident until after the publication of the results of the ExTRACT-TIMI 25 study in 2006. There was a nonsignificant 8% lower risk of death observed with LMWH compared with UFH during hospitalization or at days 7 (P=.10) and 30 (P=.08) (Table) .
All of the estimates obtained from our updated analysis are similar to our original meta-analysis, approximating a one-half reduction in reinfarction during hospitalization or at day 7 and a one-third reduction in reinfarction through day 30. There was no significant heterogeneity among the trials for any of the outcomes examined, and the data from this meta-analysis represent the best esti- Recent identification of significant adverse effects associated with newly approved prescription drugs support the sometimesheld view that a new system needs to be introduced. The present voluntary system has not provided a sufficient early warning system, and some have called for active systems that probe for potential adverse effects of approved prescription drugs. 1 Patient-oriented Web sites may provide an opportunity to identify potential adverse effects early in a drug's postmarket history.
In 2005, Wysowski and Chang 2 published a letter regarding a series of case reports submitted to the Food and Drug Administration (FDA) on severe bone, joint, and muscle pain associated with the use of alendronate so- 
